Effect of Smoking Cessation on Tuberculosis Treatment Outcomes
Primary Purpose
Tuberculosis, Pulmonary
Status
Completed
Phase
Not Applicable
Locations
Pakistan
Study Type
Interventional
Intervention
Bupropion
Behavioural Change Communication
Sponsored by
About this trial
This is an interventional supportive care trial for Tuberculosis, Pulmonary focused on measuring smoking cessation
Eligibility Criteria
Inclusion Criteria:
- pulmonary tuberculosis patients of age 18 years or above
- registered under Directly Observed Treatment Short course (DOTS) at Ojha Institute of Chest Diseases
- reported to have smoked 100 plus cigarettes in past and currently smoking cigarettes
Exclusion Criteria:
- Extra pulmonary tuberculosis
- drug resistant tuberculosis
- pregnancy
- positive history of epilepsy
Sites / Locations
- Dow University of Health Sciences
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
No Intervention
Arm Label
Bupropion
Behavioural Change Communication
Control
Arm Description
Outcomes
Primary Outcome Measures
Percentage of patients completing anti-tuberculosis treatment
Among both smear positive and smear negative TB patients, successful completion of ATT will be labeled at the end of 6 months period if the patients has been compliant with ATT through six months period..
Secondary Outcome Measures
Percentage of participants achieving abstinence from smoking
Abstinence is defined as staying away from smoking and it will be assessed at week 1, week 4, week 12 and week 24 will be assessed in following two ways:
i. Self-reported abstinence using questionnaire ii. Expired carbon monoxide (eCO) levels using Micro Smokerlyzer (Bedfont Scientific) of less than 7 ppm.
Full Information
NCT ID
NCT04848246
First Posted
April 4, 2021
Last Updated
April 13, 2021
Sponsor
Dow University of Health Sciences
1. Study Identification
Unique Protocol Identification Number
NCT04848246
Brief Title
Effect of Smoking Cessation on Tuberculosis Treatment Outcomes
Official Title
Efficacy of Smoking Cessation Interventions on Tuberculosis Treatment Outcomes Among Newly Diagnosed Pulmonary Tuberculosis Patients; a Single Blind Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
April 2021
Overall Recruitment Status
Completed
Study Start Date
November 6, 2017 (Actual)
Primary Completion Date
September 30, 2019 (Actual)
Study Completion Date
October 15, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Dow University of Health Sciences
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study was a Randomized Controlled Trial conducted at Ojha Institute of Chest Diseases, Dow University of Health Sciences, Karachi, among pulmonary tuberculosis patients
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tuberculosis, Pulmonary
Keywords
smoking cessation
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
A total of three groups, two intervention and one control
Masking
Outcomes Assessor
Masking Description
Outcome assessor for tuberculosis outcomes at the study site were blinded in terms of intervention allocation
Allocation
Randomized
Enrollment
292 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Bupropion
Arm Type
Experimental
Arm Title
Behavioural Change Communication
Arm Type
Experimental
Arm Title
Control
Arm Type
No Intervention
Intervention Type
Drug
Intervention Name(s)
Bupropion
Intervention Description
This group received Bupropion 150 mg twice daily for 10 weeks
Intervention Type
Behavioral
Intervention Name(s)
Behavioural Change Communication
Intervention Description
This group will receive Behavioural Change Communication
Primary Outcome Measure Information:
Title
Percentage of patients completing anti-tuberculosis treatment
Description
Among both smear positive and smear negative TB patients, successful completion of ATT will be labeled at the end of 6 months period if the patients has been compliant with ATT through six months period..
Time Frame
six months
Secondary Outcome Measure Information:
Title
Percentage of participants achieving abstinence from smoking
Description
Abstinence is defined as staying away from smoking and it will be assessed at week 1, week 4, week 12 and week 24 will be assessed in following two ways:
i. Self-reported abstinence using questionnaire ii. Expired carbon monoxide (eCO) levels using Micro Smokerlyzer (Bedfont Scientific) of less than 7 ppm.
Time Frame
six months
Other Pre-specified Outcome Measures:
Title
Percentage of patients defaulting anti-tuberculosis treatment.
Description
Treatment default will be defined as interruption of anti-tuberculosis treatment for ≥2 consecutive months. This outcome will be assessed in both smear positive and smear negative patients.
Time Frame
Six Months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
pulmonary tuberculosis patients of age 18 years or above
registered under Directly Observed Treatment Short course (DOTS) at Ojha Institute of Chest Diseases
reported to have smoked 100 plus cigarettes in past and currently smoking cigarettes
Exclusion Criteria:
Extra pulmonary tuberculosis
drug resistant tuberculosis
pregnancy
positive history of epilepsy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Muhammad Tahir Rizwan Khan, M.Phil.
Organizational Affiliation
Dow University of Health Sciences
Official's Role
Principal Investigator
Facility Information:
Facility Name
Dow University of Health Sciences
City
Karachi
State/Province
Sindh
Country
Pakistan
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Effect of Smoking Cessation on Tuberculosis Treatment Outcomes
We'll reach out to this number within 24 hrs